Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Open accessThe DOI matches its Crossref record; 339 of the 341 references it cites were found in a registry or an index.
Abstract
Background: Pharmacological augmentation is a recommended strategy for patients with treatment-resistant depression. A range of guidelines provide advice on treatment selection, prescription, monitoring and discontinuation, but variation in the content and quality of guidelines may limit the provision of objective, evidence-based care. This is of importance given the side effect burden and poorer long-term outcomes associated with polypharmacy and treatment-resistant depression. This review provides a definitive overview of pharmacological augmentation recommendations by assessing the quality of guidelines for depression and comparing the recommendations made. Methods: A systematic literature search identified current treatment guidelines for depression published in English. Guidelines were quality assessed using the Appraisal of Guidelines for Research and Evaluation II tool. Data relating to the prescription of pharmacological augmenters were extracted from those developed with sufficient rigor, and the included recommendations compared. Results: Total of 1696 records were identified, 19 guidelines were assessed for quality, and 10 were included. Guidelines differed in their quality, the stage at which augmentation was recommended, the agents included, and the evidence base cited. Lithium and atypical antipsychotics were recommended by all 10, though the specific advice was not consistent. Of the 15 augmenters identified, no others were universally recommended. Conclusions: This review provides a comprehensive overview of current pharmacological augmentation recommendations for major depression and will support clinicians in selecting appropriate treatment guidance. Although some variation can be accounted for by date of guideline publication, and limited evidence from clinical trials, there is a clear need for greater consistency across guidelines to ensure patients receive consistent evidence-based care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–339 of 339
Pharmacologic Treatment of Depression in Patients With Heart Disease
Roose, S. P., & Miyazaki, M. (2005) · Psychosomatic Medicine · doi:10.1097/01.psy.0000163455.43226.bf · Cited by 76
Augmentation strategies in depression 2000.
Jc, N. (2000) · PubMed · Cited by 75
Madhoo, M., Keefe, R. S., Roth, R. M., Sambunaris, A., Wu, J., Trivedi, M. H., Anderson, C. S., & Lasser, R. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.334 · Cited by 74
Abou-Saleh, M. T., Müller-Oerlinghausen, B., & Coppen, A. J. (2017) · International Journal of Bipolar Disorders · doi:10.1186/s40345-017-0080-x · Cited by 74
Bauer, M., Dell’Osso, L., Kasper, S. F., Pitchot, W., Vansvik, E. D., Köhler, J., Jørgensen, L., & Montgomery, S. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.079 · Cited by 73
Continuation and maintenance therapy in depression
Paykel, E. S. (2001) · British Medical Bulletin · doi:10.1093/bmb/57.1.145 · Cited by 73
Ninan, P. T., Hassman, H. A., Glass, S. J., & McManus, F. C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0318 · Cited by 72
Brandl, E. J., Tiwari, A. K., Zhou, X., Deluce, J. E., Kennedy, J. L., Müller, D., & Richter, M. A. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.12 · Cited by 72 · cited 1×
“CANMAT similarly cautioned against concomitant administration of cytochrome P450 inhibitors (Spina et al., 2012; Brandl et al., 2014).”
BackgroundMurray-Thomas, T., Jones, M. E., Patel, D., Brunner, E., Shatapathy, C. C., Motsko, S., & Van Staa, T. P. (2013) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2013/247486 · Cited by 72 · cited 1×
“, 2013), MPG Coronary heart disease/risk of sudden cardiac death MPG (Ray et al., 2001; Hennessy et al., 2002; Reilly et al., 2002; Straus et al., 2004; Liperoti et al., 2005; Osborn et al., 2007; Stroup et al., 2009; Murray-Thomas et al., 2013) Extrapyramidal side effects (including tardive dyskinesia and neuroleptic…”
BackgroundRobinson, D. G., Schooler, N. R., Correll, C. U., John, M., Kurian, B. T., Marcy, P., Miller, A. L., Pipes, R., Trivedi, M. H., & Kane, J. M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16080919 · Cited by 72
Buspirone Augmentation of Antidepressant Therapy
Dimitriou, E. C., & Dimitriou, C. E. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199812000-00009 · Cited by 70 · cited 2×
“, 2006b) plus 2 case series/chart reviews reporting beneficial results (Bouwer and Stein, 1997; Dimitriou and Dimitriou, 1998).”
BackgroundResultValproate as an antidepressant in major depressive disorder.
Davis, L. L., Kabel, D., Patel, D., Choate, A., Foslien-Nash, C., Gurguis, G. N. M., Kramer, G. L., & Petty, F. (1996) · PubMed · Cited by 69
Dodd, S., Mitchell, P. B., Bauer, M., Yatham, L., Young, A. H., Kennedy, S. H., Williams, L., Suppes, T., Lopez Jaramillo, C., Trivedi, M. H., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1379609 · Cited by 68 · cited 1×
“A recent consensus statement pertaining to antidepressant adverse events confirmed the need for adequate risk assessment and safety monitoring when initiating pharmacological treatment for depression (Dodd et al., 2018), and so this should be an essential part of any treatment guideline, particularly where polypharmac…”
BackgroundSelf-citationVerdolini, N., Hidalgo‐Mazzei, D., Murru, A., Pacchiarotti, I., Samalin, L., Young, A. H., Vieta, E., & Carvalho, A. F. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12896 · Cited by 67
Self-citationEsketamine is approved in Europe for treating resistant major depressive disorder
Mahase, E. (2019) · BMJ · doi:10.1136/bmj.l7069 · Cited by 67 · cited 1×
“Intranasal esketamine has now been approved by the US Food and Drug Administration (FDA, 2019) and European Medicines Agency (Mahase, 2019), and we can therefore expect its inclusion in future treatment guidelines.”
BackgroundAcute Lithium Intoxication and Neuroleptic Malignant Syndrome
Gill, J., Singh, H., & NUGENT, K. M. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.6.811.32179 · Cited by 66
Antipsychotics and Venous Thromboembolism Risk: A Meta-Analysis
Zhang, R., Dong, L., Shao, F., Tan, X., & Ying, K. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1280814 · Cited by 65 · cited 1×
“, 2010) Sexual dysfunction MPG Increased risk of pneumonia MPG Increased risk of thromboembolism MPG (Zhang et al., 2011; Barbui et al., 2014)”
BackgroundSchindler, F., & Anghelescu, I. G. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328014823d · Cited by 65
Effect of Antipsychotic Medications on Glucose and Lipid Levels
Chaggar, P. S., Shaw, S. M., & Williams, S. G. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010368678 · Cited by 65
Antipsychotics and Abnormal Liver Function Tests: Systematic Review
Marwick, K. F. M., Taylor, M., & Walker, S. W. (2012) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31826818b6 · Cited by 64 · cited 1×
“The MPG stated that at least 1 abnormal liver function test is common and rarely results in significant liver damage (Marwick et al., 2012), and the majority of side effects are dose dependent.”
BackgroundHenssler, J., Bschor, T., & Baethge, C. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743715620411 · Cited by 64 · cited 5×
“BAP recommended quetiapine as first line, citing evidence indicating equal efficacy to lithium (Bauer et al., 2013a) and noting that it was the only AAP licensed for use as an augmenter in the United Kingdom at the time of publication.”
BackgroundInfluentialAdjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study.
Zusky, P. M., Biederman, J., Rosenbaum, J. F., Manschreck, T. C., Gross, C. C., Weilberg, J. B., & Gastfriend, D. R. (1988) · PubMed · Cited by 63
Gao, K., Kemp, D. E., Fein, E., Wang, Z., Fang, Y., Ganocy, S. J., & Calabrese, J. R. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09r05535gre · Cited by 63
Efficacy of fluvoxamine in treatment-refractory depression
Delgado, P. L., Price, L. H., Charney, D. S., & Heninger, G. R. (1988) · Journal of Affective Disorders · doi:10.1016/0165-0327(88)90009-2 · Cited by 63 · cited 1×
“Seven placebo-controlled trials demonstrating the efficacy of lithium augmentation were mentioned, though not all were referenced (Delgado et al., 1988; Joffe et al., 1993; Katona et al., 1995; Baumann et al., 1996).”
BackgroundAugmentation of Antidepressants with Atypical Antipsychotics: A Review of the Current Literature
PHILIP, N. S., CARPENTER, L. L., TYRKA, A. R., & PRICE, L. H. (2008) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000308493.93003.92 · Cited by 62
Trivedi, M. H., Thase, M. E., Osuntokun, O., Henley, D. B., Case, M., Watson, S. B., Campbell, G. M., & Corya, S. A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04064 · Cited by 62
Szymkowicz, S. M., Finnegan, N., & Dale, R. M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.015 · Cited by 61 · cited 1×
“, the ICSI) included multiple doses (Szymkowicz et al., 2013).”
The combination of duloxetine and bupropion for treatment-resistant major depressive disorder
Papakostas, G. I., Worthington, J. J., Iosifescu, D. V., Kinrys, G., Burns, A. M., Fisher, L. B., Homberger, C. H., Mischoulon, D., & Fava, M. (2006) · Depression and Anxiety · doi:10.1002/da.20181 · Cited by 61
The lithiumeter: a measured approach
Malhi, G. S., Tanious, M., & Gershon, S. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00918.x · Cited by 60
(2003) · Pharmacopsychiatry · doi:10.1055/s-2003-45135 · Cited by 59 · cited 1×
“Recommended administration for 2–4 wk and then monitor patient response (Bschor et al., 2003).”
BackgroundFDA Warns of Adverse Events Linked to Smoking Cessation Drug and Antiepileptics
Kuehn, B. M. (2008) · JAMA · doi:10.1001/jama.299.10.1121 · Cited by 59 · cited 3×
“Intranasal esketamine has now been approved by the US Food and Drug Administration (FDA, 2019) and European Medicines Agency (Mahase, 2019), and we can therefore expect its inclusion in future treatment guidelines.”
BackgroundFang, Y., Yuan, C., Xu, Y., Chen, J., Wu, Z., Cao, L., Yi, Z., Hong, W., Wang, Y., Jiang, K., et al. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822bb1d9 · Cited by 59
Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine
Citrome, L., Macher, J.-P., Salazar, D. E., Mallikaarjun, S., & Boulton, D. W. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318056f309 · Cited by 59
Trivedi, M. H., Cutler, A. J., Richards, C., Lasser, R., Geibel, B. B., Gao, J., Sambunaris, A., & Patkar, A. A. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08360 · Cited by 58
Evidence Report: Treatment of Depression - Newer Pharmacotherapies
(1999) · Pharmacopsychiatry · doi:10.1055/s-2007-991098 · Cited by 57 · cited 2×
“WFSBP noted that lithium was effective in preventing suicide/suicide attempts, but it is not known if it has acute antisuicide effects (Coppen et al., 1990; Thies-Flechtner et al., 1996; Tondo et al., 1997; Müller-Oerlinghausen, 1999; Schou, 2000; Guzzetta et al., 2007; Lauterbach et al., 2008; Cipriani et al., 2013).”
BackgroundDunlop, B. W., Crits-Christoph, P., Evans, D. L., Hirschowitz, J., Solvason, H. B., Rickels, K., Garlow, S. J., Gallop, R. J., & Ninan, P. T. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815abefb · Cited by 56 · cited 2×
“Despite this, APA highlighted modafinil as the best treatment for fatigue and hypersomnolence when combined with an SSRI, based on 4 studies (DeBattista et al., 2003a; Ninan et al., 2004; Dunlop et al., 2007; Fava et al., 2007).”
BackgroundA Randomized, Double-Blind, Crossover Trial of Modafinil on Mood
Taneja, I., Haman, K., Shelton, R. C., & Robertson, D. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802eb7ea · Cited by 54
Use of bupropion with SRIs and venlafaxine
Spier, S. A. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:2<73::aid-da4>3.0.co;2-6 · Cited by 53 · cited 2×
“They also referred to several case series/case reports of bupropion augmentation that described beneficial results (Marshall and Liebowitz, 1996; Bodkin et al., 1997; Spier, 1998).”
BackgroundPsychostimulant augmentation of second generation antidepressants: A case series
Masand, P. S., Anand, V. S., & Tanquary, J. F. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:2<89::aid-da8>3.0.co;2-0 · Cited by 53 · cited 1×
“APA also advised that methylphenidate or dextroamphetamine may be useful (Masand et al., 1998; Lavretsky et al., 2006; Ravindran et al., 2008) but cautioned that not all clinical trials have shown benefits (Patkar et al.”
BackgroundIntraventricular conduction delay after bupropion overdose
Curry, S. C., Kashani, J., LoVecchio, F., & Holubek, W. J. (2005) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2005.01.027 · Cited by 52
Bauer, M., Baur, H., Berghöfer, A., Ströhle, A., Hellweg, R., Müller-Oerlinghausen, B., & Baumgartner, A. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00363-3 · Cited by 52
Adjunct Low Dose Lithium Carbonate in Treatment-Resistant Depression: A Placebo-Controlled Study
ZUSKY, P. M., BIEDERMAN, J., ROSENBAUM, J. F., MANSCHRECK, T. C., GROSS, C. C., WEILBERG, J. B., & GASTFRIEND, D. R. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198804000-00007 · Cited by 52 · cited 1×
“They included 10 eligible RCTs, all of which were between 1 and 6 weeks in length and had been included in their previous guidelines (Zusky et al., 1988; Jensen et al., 1992; Joffe et al., 1993; Stein and Bernadt, 1993; Baumann et al., 1996; Shahal et al., 1996; Bloch et al., 1997; Cappiello et al., 1998; Januel et al…”
BackgroundDo the old psychostimulant drugs have a role in managing treatment‐resistant depression?
Parker, G., & Brotchie, H. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01434.x · Cited by 51
Santos, M. A., Rocha, F. L., & Hara, C. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0302 · Cited by 51
Maneeton, N., Maneeton, B., Srisurapanont, M., & Martin, S. D. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-160 · Cited by 51 · cited 1×
“The ICSI referred to a review of 3 placebo-controlled RCTs of quetiapine extended release (XR), reporting it to be effective for response and remission (Maneeton et al., 2012), and stressed that efficacy and safety should be assessed frequently (Wright et al.”
BackgroundLess frequent lithium administration and lower urine volume
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.2.189 · Cited by 51
An Open-Label Trial of Quetiapine for Antipsychotic-Induced Sexual Dysfunction
BYERLY, M. J., LESCOUFLAIR, E., WEBER, M. T., BUGNO, R. M., FISHER, R., CARMODY, T., VARGHESE, F., & RUSH, A. J. (2004) · Journal of Sex & Marital Therapy · doi:10.1080/00926230490465082 · Cited by 49
Coffee and cigarette use: association with suicidal acts in 352 Sardinian bipolar disorder patients
Baethge, C., Tondo, L., Lepri, B., & Baldessarini, R. J. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00727.x · Cited by 49
A 6-Month Prospective Observational Study on the Effects of Quetiapine on Sexual Functioning
Montejo Gonz??lez, A. L., Rico-Villademoros, F., Tafalla, M., & Majadas, S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000186872.04984.56 · Cited by 48
Andersen, S. W., Clemow, D. B., & Corya, S. A. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1118 · Cited by 48 · cited 1×
“Weight gain APA (Andersen et al., 2005), TMAP, RANZCP Other metabolic complications/metabolic syndrome RANZCP”
BackgroundŁojko, D., & RYBAKOWSKI, J. K. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.01.016 · Cited by 47
McAllister-Williams, R. H., Anderson, I. M., Finkelmeyer, A., Gallagher, P., Grunze, H. C. R., Haddad, P. M., Hughes, T., Lloyd, A. J., Mamasoula, C., McColl, E., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00436-8 · Cited by 47
Bech, P., Fava, M., Trivedi, M. H., Wisniewski, S. R., & Rush, A. J. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01791.x · Cited by 46 · cited 2×
“, 2006b), highlighting the modified intention to treat analysis in which buspirone was less effective (Bech et al., 2012).”
BackgroundResultEffects of Hepatic or Renal Impairment on the Pharmacokinetics of Aripiprazole
Mallikaarjun, S., Shoaf, S. E., Boulton, D. W., & Bramer, S. L. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847080-00003 · Cited by 46
ECG Conduction Delays Associated with Massive Bupropion Overdose
Paris, P. A., & Saucier, J. R. (1998) · Journal of Toxicology Clinical Toxicology · doi:10.3109/15563659809028055 · Cited by 46
Frye, M. A., Yatham, L. N., Ketter, T. A., Goldberg, J. H., Suppes, T. M., Calabrese, J. R., Bowden, C. L., Bourne, E. J., Bahn, R. S., & Adams, B. E. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01343.x · Cited by 45
Zisook, S., Kasckow, J. W., Lanouette, N. M., Golshan, S., Fellows, I., Vahia, I., Mohamed, S., & Rao, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05699gre · Cited by 45 · cited 5×
“BAP recommended quetiapine as first line, citing evidence indicating equal efficacy to lithium (Bauer et al., 2013a) and noting that it was the only AAP licensed for use as an augmenter in the United Kingdom at the time of publication.”
BackgroundInfluentialWFSBP guidelines on how to grade treatment evidence for clinical guideline development
Hasan, A., Bandelow, B., Yatham, L. N., Berk, M., Falkai, P., Möller, H.-J., Kasper, S., & WFSBP Guideline Task Force Chairs (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1557346 · Cited by 44 · cited 1×
“…the use of a consistent evidence grading system such as the recent WFSBP guidelines on how to grade treatment evidence for guideline development (Hasan et al., 2019), may improve the overall quality of treatment guidelines and support greater alignment between future recommendations…”
MethodAripiprazole as an adjunctive treatment for refractory major depression
Hellerstein, D. J. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.06.016 · Cited by 43
Zullino, D., & Baumann, P. (2001) · Pharmacopsychiatry · doi:10.1055/s-2001-15873 · Cited by 43
T 3 Augmentation in Major Depressive Disorder: Safety Considerations
Rosenthal, L. J., Goldner, W. S., & O’Reardon, J. P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10030402 · Cited by 42
A new atypical antipsychotic: quetiapine-induced sexual dysfunctions
Atmaca, M., Kuloglu, M., & Tezcan, E. (2005) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901260 · Cited by 42
Bschor, T., Berghöfer, A., Ströhle, A., Kunz, D., Adli, M., Müller-Oerlinghausen, B., & Bauer, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00016 · Cited by 42 · cited 2×
“Efficacy of lithium maintenance treatment well established (Coppen et al., 1990; Schou, 1997; Davis et al., 1999; Bauer et al., 2000; Paykel, 2001; Bschor et al., 2002).”
BackgroundLong-term lithium and mortality
Coppen, A. J., Standish‐Barry, H. M. A. S., Bailey, J., Houston, G., Silcocks, P. B. S., & Hermon, C. (1990) · The Lancet · doi:10.1016/0140-6736(90)91232-y · Cited by 41 · cited 2×
“Efficacy of lithium maintenance treatment well established (Coppen et al., 1990; Schou, 1997; Davis et al., 1999; Bauer et al., 2000; Paykel, 2001; Bschor et al., 2002).”
BackgroundWen, X. J., Wang, L. M., Liu, Z. L., Huang, A., Liu, Y. Y., & Hu, J. Y. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20143672 · Cited by 41
Carbamazepine for treatment-resistant melancholia.
Cullen, M., Mitchell, P. B., Brodaty, H., Boyce, P. M., Parker, G. B., Hickie, I. B., & Wilhelm, K. A. (1991) · PubMed · Cited by 40
???Atypical?? Antidepressants in Overdose
Buckley, N. A., & Faunce, T. (2003) · Drug Safety · doi:10.2165/00002018-200326080-00002 · Cited by 39
Garakani, A., Martinez, J. M., Marcus, S., Weaver, J., Rickels, K., Fava, M., & Hirschowitz, J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328301a74c · Cited by 39
Schwartz, T. L., Azhar, N., Cole, K., Hopkins, G., Nihalani, N., Simionescu, M., Husain, J., & Jones, N. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0910 · Cited by 38 · cited 1×
“The ICSI recommended modafinil in addition to a TCA or SSRI, calling this a “jump-start response” and citing open-label studies demonstrating benefit for sleepiness and fatigue (Ninan et al., 2004; Schwartz et al., 2004).”
BackgroundPredictors of efficacy in lithium augmentation for treatment-resistant depression
Sugawara, H., Sakamoto, K., Harada, T., & Ishigooka, J. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.12.025 · Cited by 38
Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis
Berghöfer, A. (2013) · BMJ · doi:10.1136/sbmj.f5578 · Cited by 37
Antidepressant Drugs: Indications and Guidelines for Use in Epilepsy
Schmitz, B. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.043s2014.x · Cited by 36 · cited 2×
“APA also cautioned that anticonvulsant compounds may negatively impact mood (Schmitz, 2002), as some, including barbiturates and potentially vigabatrin, have been associated with an increased risk of depression (Levinson and Devinsky, 1999) supported by a statement from the US Food and Drug…”
BackgroundSmith, R. C., Lindenmayer, J., Hu, Q., Kelly, E., Viviano, T. F., Cornwell, J., Vaidhyanathaswamy, S., Marcovina, S. M., & Davis, J. M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.04.001 · Cited by 36
Drug‐drug interactions as a determinant of elevated lithium serum levels in daily clinical practice
Wilting, I., Movig, K. L. L., Moolenaar, M., Hekster, Y. A., Brouwers, J. R. B. J., Heerdink, E. R., Nolen, W. A., & Egberts, T. C. G. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00199.x · Cited by 36
Tranylcypromine Plus Risperidone for Treatment-Refractory Major Depression
Stoll, A. L., & Haura, G. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200008000-00020 · Cited by 36
Suicidal Behavior and Prophylactic Lithium Treatment of Major Mood Disorders: A Review of Reviews
Schou, M. (2000) · Suicide and Life-Threatening Behavior · doi:10.1111/j.1943-278x.2000.tb00993.x · Cited by 35
Risperidone failed to improve polydipsia‐hyponatremia of the schizophrenic patients
Kawai, N., Baba, A., & Suzuki, T. (2002) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2002.00937.x · Cited by 34 · cited 2×
“General Side Effects for AAPs Side effect Guideline(s) Weight gain APA (Andersen et al., 2005), TMAP, RANZCP Other metabolic complications/metabolic syndrome RANZCP Glucose dysregulation/diabetes mellitus APA Dyslipidaemia Hypertriglyceridemia (APA), hypercholesterolemia and hyperglycemia (particularly for olanzapine;…”
BackgroundPharmacokinetic and clinical observations on prolonged administration of flunitrazepam
Wickstr�m, E., Amrein, R., Haefelfinger, P., & Hartmann, D. (1980) · European Journal of Clinical Pharmacology · doi:10.1007/bf00561899 · Cited by 34
Dubé, S., Tollefson, G. D., Thase, M. E., Briggs, S. D., Campen, L. E. V., Case, M. G., & Tohen, M. F. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00491.x · Cited by 34
Is lithium monitoring NICE? Lithium monitoring in a UK secondary care setting
Nikolova, V. L., Pattanaseri, K., Hidalgo‐Mazzei, D., Taylor, D. M., & Young, A. H. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118760663 · Cited by 33
Self-citationKetter, T. A., Post, R. M., Parekh, P. I., & WORTHINGTON, K. (1995) · PubMed · Cited by 32
Lithium and Triiodothyronine Augmentation of Antidepressants
Joffe, R. T., Sokolov, S. T., & Levitt, A. J. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605101209 · Cited by 32 · cited 1×
“BAP also noted that lithium levels were not consistently monitored in STAR*D, and referenced 1 additional study, which although small, reported no difference between augmentation with T3, lithium, or placebo over 2 weeks (Joffe et al., 2006).”
BackgroundLuan, S., Wan, H., Wang, S., Li, H., & Zhang, B. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s127453 · Cited by 32 · cited 1×
“The MPG highlighted the risk of weight gain and limited clinical experience outside the United States and the fact that most available data are related to bipolar disorder (Luan et al., 2017).”
BackgroundBouwer, C., & Stein, D. J. (1997) · PubMed · Cited by 31
Lithium and eGFR: A new routinely available tool for the prevention of chronic kidney disease
Morriss, R. K., & Benjamin, B. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051268 · Cited by 31
Hollingshead, N. A., Meints, S. M., Middleton, S. K., Free, C. A., & Hirsh, A. T. (2015) · BMC Medical Education · doi:10.1186/s12909-015-0441-z · Cited by 30 · cited 1×
“The role of guidelines should be to support the highest standard of patient care, but instead our findings suggest that poor monitoring could be partially attributable to discrepancies between treatment guidelines, as unclear guidance has previously been cited as a problem leading to inconsistent care and may contribu…”
BackgroundZhang, Z., Tan, Q., Tong, Y., Li, Q., Kang, W.-H., Zhen, X.-C., & Post, R. M. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.11.004 · Cited by 30
Müller-Oerlinghausen, B. (1999) · PubMed · Cited by 30
Aripiprazole as an adjunctive treatment for refractory unipolar depression
Hellerstein, D. J., Batchelder, S. T., Hyler, S. E., Arnaout, B., Corpuz, V., Coram, L., & Weiss, G. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.11.024 · Cited by 30 · cited 1×
“The MPG included aripiprazole as first line, advocating a good evidence base, good tolerability and safety, and the potential efficacy of low doses, though side effects may be disadvantageous (Papakostas et al., 2005; Simon and Nemeroff, 2005; Berman et al., 2007; Hellerstein et al., 2008; Marcus et al., 2008; Fava et…”
BackgroundCardiac effects of psychotropic drugs.
Chong, S. A., Mythily, & Mahendran, R. (2001) · PubMed · Cited by 29
Venlafaxine and Bupropion Combination Therapy in a Case of Treatment-Resistant Depression
Fatemi, S. H., Emamian, E. S., & Kist, D. A. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18249 · Cited by 29 · cited 5×
“BAP recommended quetiapine as first line, citing evidence indicating equal efficacy to lithium (Bauer et al., 2013a) and noting that it was the only AAP licensed for use as an augmenter in the United Kingdom at the time of publication.”
BackgroundInfluentialChen, C., Lin, T., Wang, C., & Shuai, H. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02156.x · Cited by 28
Outcome of a 4-Step Treatment Algorithm for Depressed Inpatients
Birkenhäger, T. K., van den Broek, W. W., Moleman, P., & Bruijn, J. A. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0814 · Cited by 28
McLaughlin, T., Hogue, S. L., & Stang, P. E. (2007) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000208273.80496.3f · Cited by 28
Matsumoto, R. R., Nguyen, L., Weaver, C., Cramér, K., Pollard, S., & Marshalek, P. J. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s88569 · Cited by 28 · cited 1×
“They also cited studies of intramuscular and subcutaneous administration, sublingual administration, and transmucosal routes (Lara et al., 2013; Nguyen et al., 2015; Loo et al., 2016).”
BackgroundTurner, P., Kantaria, R., & Young, A. H. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113507640 · Cited by 28 · cited 1×
“, 2013a), a randomized open comparison with lamotrigine in which lithium was nonsignificantly better (Schindler and Anghelescu, 2007a), and a meta-analysis of EU-licensed augmenters with similar response rates for lithium, quetiapine XR, and S-adenosyl-L-methionine, though S-adenosyl-L-methionine was significantly bet…”
ResultSelf-citationImpairment in driving and psychiatric illness
Metzner, J. L., Dentino, A. N., Godard, S. L., Hay, D. P., Hay, L., & Linnoila, M. (1993) · Journal of Neuropsychiatry · doi:10.1176/jnp.5.2.211 · Cited by 28
Paroxetine/Bupropion Combination Treatment for Refractory Depression
Marshall, R. D., & Liebowitz, M. R. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199602000-00016 · Cited by 27 · cited 1×
“They also referred to several case series/case reports of bupropion augmentation that described beneficial results (Marshall and Liebowitz, 1996; Bodkin et al., 1997; Spier, 1998).”
BackgroundLithium Treatments: Single and Multiple Daily Dosing
Ljubičić, Đ., Crepulja, M. L., Vitezić, D., Bistrović, I. L., & Ljubičić, R. (2008) · The Canadian Journal of Psychiatry · doi:10.1177/070674370805300507 · Cited by 26
Yoshimura, R., Kishi, T., Hori, H., Ikenouchi, A., Katsuki, A., Umene‐Nakano, W., Iwata, N., & Nakamura, J. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.07.008 · Cited by 26 · cited 1×
“The MPG included aripiprazole as first line, advocating a good evidence base, good tolerability and safety, and the potential efficacy of low doses, though side effects may be disadvantageous (Papakostas et al., 2005; Simon and Nemeroff, 2005; Berman et al., 2007; Hellerstein et al., 2008; Marcus et al., 2008; Fava et…”
BackgroundKennedy, S. H., Segal, Z. V., Cohen, N. L., Levitan, R. D., Gemar, M., & Bagby, R. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0414 · Cited by 25
Taylor, R., Marwood, L., Greer, B., Strawbridge, R., & Cleare, A. J. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119872194 · Cited by 25
Self-citationThe use of anticonvulsants to augment antidepressant medication.
Dietrich, D. E., & Emrich, H. M. (1998) · PubMed · Cited by 23
Effects of Olanzapine on Polydipsia and Intermittent Hyponatremia
Littrell, K. H., Johnson, C. G., Littrell, S. H., & Peabody, C. D. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1206c · Cited by 23 · cited 2×
“General Side Effects for AAPs Side effect Guideline(s) Weight gain APA (Andersen et al., 2005), TMAP, RANZCP Other metabolic complications/metabolic syndrome RANZCP Glucose dysregulation/diabetes mellitus APA Dyslipidaemia Hypertriglyceridemia (APA), hypercholesterolemia and hyperglycemia (particularly for olanzapine;…”
BackgroundTakahashi, H., Kamata, M., Yoshida, K., Higuchi, H., & Ishigooka, J. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.914 · Cited by 22
Bupropion-induced hyponatremia
Kate, N., Grover, S., Kumar, S. V. R., & Modi, M. (2013) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2013.04.020 · Cited by 22
Severus, E., & Bauer, M. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-34 · Cited by 22
Lithium and desipramine versus desipramine alone in the treatment of severe major depression
Cappiello, A., McDougle, C. J., Delgado, P. L., Malison, R. T., Jatlow, P., Charney, D. S., Heninger, G. R., & Price, L. H. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199809000-00001 · Cited by 22 · cited 1×
“They included 10 eligible RCTs, all of which were between 1 and 6 weeks in length and had been included in their previous guidelines (Zusky et al., 1988; Jensen et al., 1992; Joffe et al., 1993; Stein and Bernadt, 1993; Baumann et al., 1996; Shahal et al., 1996; Bloch et al., 1997; Cappiello et al., 1998; Januel et al…”
BackgroundWooderson, S. C., Fekadu, A., Markopoulou, K., Rane, L. J., Poon, L., Juruena, M. F., Strawbridge, R., & Cleare, A. J. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.05.013 · Cited by 22 · cited 1×
“However, for the 25% to 50% of patients reported to have a poor response to at least 2 different antidepressant treatments (Fava and Davidson, 1996; Rush et al., 2006), outcomes can be improved with successive and multimodal treatment (Rush et al., 2006; Wooderson et al., 2014).”
BackgroundSelf-citationAntipsychotic drugs – information and choice: a patient survey
Olofinjana, B., & Taylor, D. M. (2005) · Psychiatric Bulletin · doi:10.1192/pb.29.10.369 · Cited by 21
Yoshimura, R., Umene‐Nakano, W., Ueda, N., Ikenouchi, A., Hori, H., & Nakamura, J. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.979 · Cited by 20
Marwood, L., Taylor, R., Goldsmith, K., Romeo, R., Holland, R., Pickles, A. R., Hutchinson, J. D., Dietch, D., Cipriani, A., Nair, R., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1393-0 · Cited by 20
Self-citationClinically Important Differences in the Pharmacokinetics of the Ten Newer “Atypical” Antipsychotics
Preskorn, S. (2012) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000415076.28497.8e · Cited by 19
A Fatal Case of Bupropion (Zyban(R)) Overdose
Mercerolle, M., Denooz, R., Lachâtre, G., & Charlier, C. (2008) · Journal of Analytical Toxicology · doi:10.1093/jat/32.2.192 · Cited by 19
Montgomery, J. H., & Tekell, J. L. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0317g · Cited by 17 · cited 2×
“General Side Effects for AAPs Side effect Guideline(s) Weight gain APA (Andersen et al., 2005), TMAP, RANZCP Other metabolic complications/metabolic syndrome RANZCP Glucose dysregulation/diabetes mellitus APA Dyslipidaemia Hypertriglyceridemia (APA), hypercholesterolemia and hyperglycemia (particularly for olanzapine;…”
BackgroundJon, D., Kim, D. H., Seo, H., Kwon, Y., Kim, M.-D., Yang, J.-C., Suh, H.-S., Min, K. J., Pae, C., & Bahk, W. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3182a31f3d · Cited by 17 · cited 1×
“The MPG included aripiprazole as first line, advocating a good evidence base, good tolerability and safety, and the potential efficacy of low doses, though side effects may be disadvantageous (Papakostas et al., 2005; Simon and Nemeroff, 2005; Berman et al., 2007; Hellerstein et al., 2008; Marcus et al., 2008; Fava et…”
BackgroundZhu, Y., KOLAWOLE, T., & Jimenez, X. F. (2016) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000179 · Cited by 17
Bupropion-Tranylcypromine Combination for Treatment-Refractory Depression
Pierre, J. M., & Gitlin, M. J. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0610h · Cited by 16
Kim, H. R., Delva, N. J., & Lawson, J. S. (1990) · The Canadian Journal of Psychiatry · doi:10.1177/070674379003500201 · Cited by 16 · cited 1×
“Lithium + AD in continuation phase more beneficial than antidepressant + placebo, AD monotherapy, or lithium monotherapy (Kim et al., 1990; Bauer et al., 2000; Bschor et al., 2002).”
BackgroundHypersexualité induite par l’aripiprazole : à propos d’un cas et revue de la littérature
Vrignaud, L., Aouillé, J., Mallaret, M., Durrieu, G., & Jonville‐Béra, A. ‐. (2014) · Therapies · doi:10.2515/therapie/2014064 · Cited by 15
Israel, J. A. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.15br01836 · Cited by 15 · cited 2×
“…stated that other augmentation options are better supported, as the evidence for stimulants (methylphenidate, dexamfetamine, and lisdexamfetamine) is generally inconclusive and inadequate (Fawcett et al., 1991; Parker and Brotchie, 2010; Trivedi et al., 2013; Madhoo et al., 2014; Israel, 2015).”
BackgroundLiver Injury Associated With Quetiapine: An Illustrative Case Report
Das, A., Guarda, L. A., & Allen, L. G. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000749 · Cited by 15
Januel, D., Massot, O., Poirier, M. F., Olié, J., & Fillion, G. (2002) · Psychiatry Research · doi:10.1016/s0165-1781(02)00136-1 · Cited by 14
Gervasoni, N., Aubry, J., Gex‐Fabry, M., Bertschy, G., & Bondolfi, G. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.11.005 · Cited by 14
Fabrazzo, M., Perris, F., Monteleone, P., Esposito, G., Catapano, F., & Maj, M. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.06.006 · Cited by 13 · cited 1×
“An RCT of aripiprazole augmentation of clomipramine was also discussed, in which Hamilton Depression Rating Scale (HDRS) scores significantly decreased each week (Fabrazzo et al., 2012).”
BackgroundConcurrent Treatment of Nonresistant Major Depression With Desipramine and Lithium
Bloch, M., Schwartzman, Y., Bonne, O. B., & Lerer, B. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199702000-00008 · Cited by 13 · cited 1×
“They included 10 eligible RCTs, all of which were between 1 and 6 weeks in length and had been included in their previous guidelines (Zusky et al., 1988; Jensen et al., 1992; Joffe et al., 1993; Stein and Bernadt, 1993; Baumann et al., 1996; Shahal et al., 1996; Bloch et al., 1997; Cappiello et al., 1998; Januel et al…”
BackgroundLithium for long-term treatment of unipolar depression
Young, A. H. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30232-8 · Cited by 13
Self-citationShahal, B., Piel, E., Mecz, L., Kremer, I., & Klein, E. (1996) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00307-1 · Cited by 12 · cited 1×
“They included 10 eligible RCTs, all of which were between 1 and 6 weeks in length and had been included in their previous guidelines (Zusky et al., 1988; Jensen et al., 1992; Joffe et al., 1993; Stein and Bernadt, 1993; Baumann et al., 1996; Shahal et al., 1996; Bloch et al., 1997; Cappiello et al., 1998; Januel et al…”
BackgroundThe effects of lithium on the immune system
(2013) · Lithium in Neuropsychiatry · doi:10.3109/9780203007051-42 · Cited by 12
A novel dosage form for buccal administration of bupropion
Almeida, N. M. G., de Lima, R., Alves, T. F. R., Rebelo, M. D. A., Severino, P. B., & Chaud, M. V. (2015) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502015000100010 · Cited by 10
Vieta, E., Bauer, M., Montgomery, S., McIntyre, R. S., Szamosi, J., Earley, W. R., & Eriksson, H. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.052 · Cited by 10
[Chronic renal function disorders during lithium use].
van Gerven, H. A. J. M., & Boer, W. H. (2006) · PubMed · Cited by 8
Bupropion-Associated Withdrawal Symptoms Revisited
Berigan, T. R. (2002) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v04n0208a · Cited by 8 · cited 1×
“The MPG advised that bupropion discontinuation symptoms, similar to those associated with SSRI use, have been documented in a few cases, but this was not specific to its use as an augmenter (Berigan and Harazin, 1999; Berigan, 2002).”
BackgroundBupropion-Associated Withdrawal Symptoms
Berigan, T. R., & Harazin, J. S. (1999) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v01n0205 · Cited by 8 · cited 1×
“Discontinuation The MPG advised that bupropion discontinuation symptoms, similar to those associated with SSRI use, have been documented in a few cases, but this was not specific to its use as an augmenter (Berigan and Harazin, 1999; Berigan, 2002).”
BackgroundBerger, M., Riedel, M. J., Tomova, N., Obermeier, M., Seemüller, F., Dittmann, S., Mœller, H., & Severus, E. (2013) · International Journal of Bipolar Disorders · doi:10.1186/2194-7511-1-7 · Cited by 8
Bupropion fails to affect plasma prolactin and growth hormone in normal subjects [letter]
Pd, W., Peck, A., Fowle, A. S. E., & Smith, P. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb01450.x · Cited by 8
Aubry, R., Scott, L. R., & Cassidy, E. (2017) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2017.2 · Cited by 8 · cited 1×
“Another review stated that only 60% of clinical trials and audits met safety monitoring standards for the prescription of lithium in the United Kingdom, and none fully met the recommendations (Aubry et al., 2017).”
BackgroundP01-75 - Quetiapine XR or Lithium Combination with Antidepressants in Treatment Resistant Depression
Montgomery, S., Dell’Osso, L., Kasper, S. F., Pitchot, W., Vansvik, E. D., Köhler, J., Jörgensen, L., & Bauer, M. (2010) · European Psychiatry · doi:10.1016/s0924-9338(10)70294-7 · Cited by 2
Mosolov, S. N., Mv, K., Mg, U., Misionzhhnik, E. I., & Ryzhov, A. M. (1997) · PubMed · Cited by 2
Research works printed but not linked: 12
- Agid, 2006, The “delayed onset” of antipsychotic action–an idea whose time has come and gone, J Psychiatry Neurosci, 31, 93
- DeBattista, 2003, Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study, J Clin Psychiatry, 64, 1057, 10.4088/JCP.v64n0911 · DOI · Paper page
- FDA, 2019, February 12, 2019: Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee - 02/12/2019 - 02/12/2019
- Fond, 2014, Ketamine administration in depressive disorders: a systematic review and meta-analysis, Psychopharmacology (Berl), 231, 3663, 10.1007/s00213-014-3664-5 · DOI · Paper page
- Hurley, 2002, Lamotrigine update and its use in mood disorders, Ann Pharmacother, 36, 860, 10.1345/aph.1A102 · doi:10.1345/aph.1a102 · Paper page
- Jensen, 1992, Combining nortriptyline and lithium in elderly depressed patients: a double-blind, placebo-controlled study, Lithium, 3, 259
- National Institute for Health and Clinical Excellence (NICE), 2009, The treatment and management of depression in adults (Updated Edition)
- Schindler, 2007, Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study, Int Clin Psychopharmacol, 22, 179, 10.1097/YIC.0b013e328014823d · DOI · Paper page
- Serafini, 2014, The role of ketamine in treatment-resistant depression: a systematic review, Curr Neuropharmacol, 12, 444, 10.2174/1570159X12666140619204251 · DOI · Paper page
- Suehs, 2008, Texas medication algorithm project procedural manual: major depressive disorder algorithms. Austin, TX: The Texas Department of State Health Services
- Taylor, 2015, The Maudsley prescribing guidelines in psychiatry
- Trivedi, 2006, Medication augmentation after the failure of SSRIs for depression, N Engl J Med, 354, 1243, 10.1056/NEJMoa052964 · DOI · Paper page
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationSforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01381-x · Cited by 214
“Moreover, guidelines on how to treat TRD/PRD, such as pharmacological augmentation, are not consistent [14], and evidence on effectiveness is sparse [15].”
BackgroundSelf-citationMalhi, G. S., Bell, E., Singh, A., Bassett, D. L., Berk, M., Boyce, P. M., Bryant, R. A., Gitlin, M. J., Hamilton, A., Hazell, P., et al. (2020) · Bipolar Disorders · doi:10.1111/bdi.13035 · Cited by 131
Self-citationScott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221104058 · Cited by 87
“The exception to this rule was buspirone, for which the ES and 95% CIs were considerably higher when TRD was defined as 2 FTs (1 FT = ES = 0.84, 95% CI: 0.61–1.07; 2 FTs = ES = 1.57, 95% CI: 1.14–2.02), although this consisted of only one small study.”
BackgroundResultInfluentialSelf-citationLevkovich, I., & Elyoseph, Z. (2023) · Family Medicine and Community Health · doi:10.1136/fmch-2023-002391 · Cited by 83
“Scrutiny and handling of gender or socioeconomic biases.”
Background
Metadata
- Authors
- Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J.
- Affiliations
- King's College London (GB)
- The Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, De Crespigny Park, London, United Kingdom
- Oxford Health NHS Foundation Trust (GB)
- University of Geneva (CH)
- Corresponding author
- Marwood, Lindsey
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-05-13
- Volume
- 23
- Issue
- 9
- Pages
- 587-625
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7710919
- OpenAlex
- W3024119889
- Cited by
- 76
- References
- 341
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 16 · 2023: 17 · 2022: 9 · 2021: 15 · 2020: 3
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute for Health Research
- South London and Maudsley NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- drug augmentation, treatment-resistant depression, major depressive disorder, guideline quality, lithium, atypical antipsychotics, polypharmacy, evidence-based care, guideline recommendations
- MeSH terms
- Major Depressive Disorder, Drug Synergism, Drug Therapy, Combination, Humans, Drug Prescriptions, Antipsychotic Agents, Practice Guidelines as Topic, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
